517 related articles for article (PubMed ID: 16738695)
21. Therapeutic options for patients returning to sexual activity.
Nusbaum MR
J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S2-5. PubMed ID: 15083992
[TBL] [Abstract][Full Text] [Related]
22. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
[TBL] [Abstract][Full Text] [Related]
23. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
25. Vardenafil treatment for erectile dysfunction.
Crowe SM; Streetman DS
Ann Pharmacother; 2004 Jan; 38(1):77-85. PubMed ID: 14742800
[TBL] [Abstract][Full Text] [Related]
26. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
Brock G; Chan J; Carrier S; Chan M; Salgado L; Klein AH; Lang C; Horner R; Gutkin S; Dickson R
BJU Int; 2007 Feb; 99(2):376-82. PubMed ID: 17155989
[TBL] [Abstract][Full Text] [Related]
27. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Fleshner N; Harvey M; Adomat H; Wood C; Eberding A; Hersey K; Guns E
J Urol; 2005 Aug; 174(2):636-41; discussion 641; quiz 801. PubMed ID: 16006928
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Firoozi F; Longhurst PA; White MD
BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
[TBL] [Abstract][Full Text] [Related]
30. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].
Jin W; Huang YR
Zhonghua Nan Ke Xue; 2005 Sep; 11(9):708-12. PubMed ID: 16209216
[TBL] [Abstract][Full Text] [Related]
32. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
33. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
35. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
38. The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment.
Rosen RC; Fisher WA; Beneke M; Homering M; Evers T
BJU Int; 2007 Apr; 99(4):849-59. PubMed ID: 17378845
[TBL] [Abstract][Full Text] [Related]
39. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Agarwal P; Sander GE; Giles TD
Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
